Literature DB >> 23396374

Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression.

Zhi-feng Wei1, Xiao-lan Jiao, Ting Wang, Qian Lu, Yu-feng Xia, Zheng-tao Wang, Qing-long Guo, Gui-xin Chou, Yue Dai.   

Abstract

AIM: To explore the effects of norisoboldine (NOR), a major isoquinoline alkaloid in Radix Linderae, on joint destruction in rats with adjuvant-induced arthritis (AIA) and its underlying mechanisms.
METHODS: AIA was induced in adult male SD rats by intradermal injection of Mycobacterium butyricum in Freund's complete adjuvant at the base of the right hind paw and tail. From d 14 after immunization, the rats were orally given NOR (7.5, 15, or 30 mg/kg) or dexamethasone (0.5 mg/kg) daily for 10 consecutive days. Joint destruction was evaluated with radiological scanning and H&E staining. Fibroblast-like synoviocytes (FLS) were prepared from fresh synovial tissues in the AIA rats. The expression of related proteins and mRNAs were detected by ELISA, Western blotting and RT-PCR.
RESULTS: In AIA rats, NOR (15 and 30 mg/kg) significantly decreased the swelling of paws and arthritis index scores, and elevated the mean body weight. NOR (30 mg/kg) prevented both the infiltration of inflammatory cells and destruction of bone and cartilage in joints. However, NOR (15 mg/kg) only suppressed the destruction of bone and cartilage, but did not obviously ameliorate synovial inflammation. NOR (15 and 30 mg/kg) significantly decreased the serum levels of receptor activator of nuclear factor κB ligand (RANKL), IL-6, PGE2, and MMP-13, but not the osteoprotegerin and MMP-1 levels. The mRNA levels of RANKL, IL-6, COX-2, and MMP-13 in synovium were also suppressed. Dexamethasone produced similar effects in AIA rats as NOR did, but without elevating the mean body weight. In the cultured FLS, treatment with NOR (10 and 30 mmol/L) significantly decreased the secretion of RANKL, IL-6, PGE2, and MMP-13 proteins. Furthermore, the treatment selectively prevented the activation of MAPKs, AKT and transcription factor AP-1 component c-Jun, but not the recruitment of TRAF6 or the activation of JAK2/STAT3. Treatment of the cultured FLS with the specific inhibitors of p38, ERK, AKT, and AP-1 significantly decreased the secretion of RANKL, IL-6, PGE2, and MMP-13 proteins.
CONCLUSION: NOR can alleviate joint destruction in AIA rats by reducing RANKL, IL-6, PGE2, and MMP-13 expression via the p38/ERK/AKT/AP-1 pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396374      PMCID: PMC4002497          DOI: 10.1038/aps.2012.187

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  47 in total

Review 1.  Pathogenesis of rheumatoid arthritis: the role of synoviocytes.

Authors:  Y Yamanishi; G S Firestein
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

2.  N-(2-hydroxy phenyl) acetamide inhibits inflammation-related cytokines and ROS in adjuvant-induced arthritic (AIA) rats.

Authors:  Huma Jawed; Syed Uzair Ali Shah; Siddiqua Jamall; Shabana Usman Simjee
Journal:  Int Immunopharmacol       Date:  2010-05-07       Impact factor: 4.932

3.  Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis.

Authors:  Salvatore Cuzzocrea; Emanuela Mazzon; Rosanna Di Paola; Tiziana Genovese; Carmelo Muià; Achille P Caputi; Daniela Salvemini
Journal:  Arthritis Rheum       Date:  2005-06

4.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

Authors:  Z Han; D L Boyle; L Chang; B Bennett; M Karin; L Yang; A M Manning; G S Firestein
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 5.  RANK ligand.

Authors:  J M Blair; Y Zheng; C R Dunstan
Journal:  Int J Biochem Cell Biol       Date:  2006-11-23       Impact factor: 5.085

6.  Norisoboldine inhibits the production of pro-inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 cells by down-regulating the activation of MAPKs but not NF-κB.

Authors:  Yubin Luo; Mei Liu; Yue Dai; Xiujuan Yao; Yufeng Xia; Guixin Chou; Zhengtao Wang
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

Review 7.  Bone and joint destruction in rheumatoid arthritis: what is really happening?

Authors:  Steven R Goldring
Journal:  J Rheumatol Suppl       Date:  2002-09

Review 8.  Role of phosphoinositide 3-kinase in innate immunity.

Authors:  Kaoru Hazeki; Kiyomi Nigorikawa; Osamu Hazeki
Journal:  Biol Pharm Bull       Date:  2007-09       Impact factor: 2.233

9.  Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.

Authors:  Thomas J Wilson; Kalyan C Nannuru; Mitsuru Futakuchi; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 10.  The role of interleukin-1 in the pathogenesis of rheumatoid arthritis.

Authors:  J Kay; L Calabrese
Journal:  Rheumatology (Oxford)       Date:  2004-06       Impact factor: 7.580

View more
  11 in total

1.  Establishment of a novel cell-based assay for screening small molecule antagonists of human interleukin-6 receptor.

Authors:  Yang-yang He; Yu Yan; Chang Zhang; Peng-yuan Li; Ping Wu; Peng Du; Da-di Zeng; Jian-song Fang; Shuang Wang; Guan-hua Du
Journal:  Acta Pharmacol Sin       Date:  2014-10-27       Impact factor: 6.150

2.  Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.

Authors:  E Aizman; E Blacher; O Ben-Moshe; T Kogan; Y Kloog; A Mor
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

3.  Increasing expression of substance P and calcitonin gene-related peptide in synovial tissue and fluid contribute to the progress of arthritis in developmental dysplasia of the hip.

Authors:  Hui Wang; Xiang Zhang; Ji-Ye He; Xin-Feng Zheng; De Li; Zheng Li; Jun-Feng Zhu; Chao Shen; Gui-Quan Cai; Xiao-Dong Chen
Journal:  Arthritis Res Ther       Date:  2015-01-12       Impact factor: 5.156

4.  Metabolomic Analysis of Biochemical Changes in the Serum and Urine of Freund's Adjuvant-Induced Arthritis in Rats after Treatment with Silkworm Excrement.

Authors:  Tianyao Zheng; Shulan Su; Xinxin Dai; Liwen Zhang; Jin-Ao Duan; Zhen Ou-Yang
Journal:  Molecules       Date:  2018-06-20       Impact factor: 4.411

5.  Mechanistic studies on the absorption enhancement of a self-nanoemulsifying drug delivery system loaded with norisoboldine-phospholipid complex.

Authors:  Jing Zhang; Xiaoxia Wen; Yue Dai; Yufeng Xia
Journal:  Int J Nanomedicine       Date:  2019-09-02

6.  Norisoboldine, an Anti-Arthritis Alkaloid Isolated from Radix Linderae, Attenuates Osteoclast Differentiation and Inflammatory Bone Erosion in an Aryl Hydrocarbon Receptor-Dependent Manner.

Authors:  Zhi-feng Wei; Qi Lv; Ying Xia; Meng-fan Yue; Can Shi; Yu-feng Xia; Gui-xin Chou; Zheng-tao Wang; Yue Dai
Journal:  Int J Biol Sci       Date:  2015-07-17       Impact factor: 6.580

7.  Quantitative analysis of the major constituents in Chinese medicinal preparation SuoQuan formulae by ultra fast high performance liquid chromatography/quadrupole tandem mass spectrometry.

Authors:  Feng Chen; Hai-Long Li; Yong-Hui Li; Yin-Feng Tan; Jun-Qing Zhang
Journal:  Chem Cent J       Date:  2013-07-30       Impact factor: 4.215

8.  Norisoboldine suppresses VEGF-induced endothelial cell migration via the cAMP-PKA-NF-κB/Notch1 pathway.

Authors:  Qian Lu; Bei Tong; Yubin Luo; Li Sha; Guixin Chou; Zhengtao Wang; Yufeng Xia; Yue Dai
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

9.  Protective effect of Asarum extract in rats with adjuvant arthritis.

Authors:  Wenqiang Zhang; Juan Zhang; Ming Zhang; Lin Nie
Journal:  Exp Ther Med       Date:  2014-08-29       Impact factor: 2.447

10.  Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis.

Authors:  Kai Guo; Xin Bu; Chongfei Yang; Xiaorui Cao; Huan Bian; Qingsheng Zhu; Jinyu Zhu; Dawei Zhang
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.